CN105412281B - A kind of Chinese medicine composition for treating allergic asthma and preparation method thereof - Google Patents

A kind of Chinese medicine composition for treating allergic asthma and preparation method thereof Download PDF

Info

Publication number
CN105412281B
CN105412281B CN201510885057.9A CN201510885057A CN105412281B CN 105412281 B CN105412281 B CN 105412281B CN 201510885057 A CN201510885057 A CN 201510885057A CN 105412281 B CN105412281 B CN 105412281B
Authority
CN
China
Prior art keywords
weight
parts
fruit
chinese medicine
medicine composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510885057.9A
Other languages
Chinese (zh)
Other versions
CN105412281A (en
Inventor
晁恩祥
萧伟
李淼
王仁杰
常秀娟
王星星
康小东
杨素德
王永香
周恩丽
吴云
孙永成
丁岗
王振中
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Kanion Pharmaceutical Co Ltd
Original Assignee
Jiangsu Kanion Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Kanion Pharmaceutical Co Ltd filed Critical Jiangsu Kanion Pharmaceutical Co Ltd
Priority to CN201510885057.9A priority Critical patent/CN105412281B/en
Publication of CN105412281A publication Critical patent/CN105412281A/en
Application granted granted Critical
Publication of CN105412281B publication Critical patent/CN105412281B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/238—Saposhnikovia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/40—Cornaceae (Dogwood family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/535—Perilla (beefsteak plant)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A61K36/575—Magnolia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/79—Schisandraceae (Schisandra family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses a kind of Chinese medicine composition for treating allergic asthma, side is made up of windproof, perilla leaf, ephedra, the fruit of Chinese magnoliavine, gingko, almond, aster, dogwood fruit, flower bud of lily magnolia etc..It is allergic asthma that we, which adapt to disease, one dispelling wind dispersing and lowering lung-QI, i.e., improves air flue contraction urgency in terms of air flue of releiving, to airway hyper-reaction with the effect of releiving；Secondly it is sensible depressing Qi and relieving asthma, for nasal obstruction, out of breath, syndrome characterized by dyspnea, the respectful drop function of improvement lung.

Description

A kind of Chinese medicine composition for treating allergic asthma and preparation method thereof
Technical field
The invention belongs to technical field of traditional Chinese medicines, and in particular to a kind of Chinese medicine composition for treating allergic asthma and its preparation Method.
Background technology
Bronchial astehma be by various kinds of cell and cellular component participation chronic airway inflammation disease, this chronic inflammation It is related to airway hyperreactivity, extensive and changeable reversible airflow limitation is generally occurred within, causes the panting of recurrent exerbation, gas The symptoms such as rush, uncomfortable in chest and (or) cough, more in night and (or) early morning breaking-out, aggravation.Whole body is livid purple when serious, serious Patient respiratory sound can suddenly disappear.
The hazards of asthma include two aspects of host factor (inherent cause) and environmental factor.Inherent cause exists Many patients can embody with it, such as among relatives' (having relationship by blood, nearly three generations people) of most patients, all Asthma (repeated coughing, panting) or other anaphylactia (allergic rhinitis, atopic dermatitis) medical histories can have been traced back to.Greatly Most asthmatic patients belong to allergic constitution, and itself may be with allergic rhinitis and atopic dermatitis, or to common through sky Allergen (acarid, pollen, pet, mould etc.), some foods (nut, milk, peanut, seafood etc.), the medicine of gas propagation Allergy etc..
At present, traditional Chinese medicine still belongs to blank in treatment allergic asthma field, and the present invention is summarizing complex treatment success and lost Lose on experiential basis, it then follows modern traditional Chinese medicine is theoretical, is studied by lot of experiments, finds a kind of effectively treatment allergic asthma Chinese medicine composition.
The content of the invention
It is an object of the invention to provide a kind of Chinese medicine composition for treating allergic asthma.
It is a further object of the present invention to provide the preparation method of the Chinese medicine composition of the treatment allergic asthma.
The purpose of the present invention is achieved in the following ways：
A kind of Chinese medicine composition for treating allergic asthma, said composition are made up of the component of following parts by weight：
It is windproof 10-15 parts by weight, perilla leaf 10-15 parts by weight, ephedra 2-6 parts by weight, fruit of Chinese magnoliavine 7-9 parts by weight, white Fruit 7-9 parts by weight, semen armeniacae amarae 7-9 parts by weight, aster 7-9 parts by weight, dogwood fruit 7-9 parts by weight, flower bud of lily magnolia 7-9 parts by weight.
The Chinese medicine composition of above-mentioned treatment allergic asthma is preferably made up of the component of following parts by weight：
It is windproof 10-12 parts by weight, perilla leaf 10-12 parts by weight, ephedra 4-6 parts by weight, fruit of Chinese magnoliavine 7-8 parts by weight, white Fruit 7-8 parts by weight, semen armeniacae amarae 7-8 parts by weight, aster 7-8 parts by weight, dogwood fruit 7-8 parts by weight, flower bud of lily magnolia 7-8 parts by weight.
The Chinese medicine composition of above-mentioned treatment allergic asthma is most preferably made up of the component of following parts by weight：
Windproof 10 parts by weight, the parts by weight of perilla leaf 10, the parts by weight of ephedra 6, the parts by weight of the fruit of Chinese magnoliavine 8, the parts by weight of gingko 8, The parts by weight of semen armeniacae amarae 8, the parts by weight of aster 8, the parts by weight of dogwood fruit 8, the parts by weight of the flower bud of lily magnolia 8.
The present invention treatment allergic asthma Chinese medicine composition add pharmacy allow auxiliary material prepare granule, capsule, Tablet or pill.
The preparation method of Chinese medicine composition of the present invention comprises the following steps：
By perilla leaf, flower bud of lily magnolia extraction by steam distillation volatile ingredient, using standby, the dregs of a decoction after beta-cyclodextrin inclusion compound Merge with windproof, ephedra, semen armeniacae amarae, add water to cook 1-3 times respectively, each 1-3 hours, merge extract solution, be condensed into 50 DEG C Under the conditions of relative density be 1.10~1.15 clear cream, alcohol is sink to alcohol content 60%-70%, takes supernatant concentration that 50 DEG C of bars are made The clear cream that relative density is 1.25~1.30 under part is standby；The fruit of Chinese magnoliavine, gingko, aster, dogwood fruit are extracted with 60%-70% ethanol 1-3 times, each 1-3 hours, merge alcohol extract, the clear cream that relative density under the conditions of 50 DEG C is 1.25~1.30 is made in concentration；Will Above-mentioned each clear cream merges, and dry, pulverize, and adds volatile oil clathrate compound, mixes, produces.
The preparation method of above-mentioned Chinese medicine composition specifically comprises the following steps：
By perilla leaf, flower bud of lily magnolia extraction by steam distillation volatile ingredient, using standby, the dregs of a decoction after beta-cyclodextrin inclusion compound Merge with windproof, ephedra, semen armeniacae amarae, respectively plus 10 times of amount decoctings are boiled 3 times, 1.5 hours every time, are merged extract solution, are condensed into Relative density is 1.10~1.15 clear cream under the conditions of 50 DEG C, and alcohol is sink to alcohol content 70%, takes supernatant concentration that 50 DEG C of bars are made The clear cream that relative density is 1.25~1.30 under part is standby；The fruit of Chinese magnoliavine, gingko, aster, dogwood fruit are extracted three times with 60% ethanol, 2.5 hours every time, merge alcohol extract, the clear cream that relative density under the conditions of 50 DEG C is 1.25~1.30 is made in concentration；Will be above-mentioned each Clear cream merges, and dry, pulverize, and adds volatile oil clathrate compound, mixes, produces.
Chinese medicine composition of the present invention is applied in the medicine for preparing treatment allergic asthma has significant effect.
The present composition is directed to the treatment of allergic asthma, one dispelling wind dispersing and lowering lung-QI, i.e., from releiving in terms of two It is anxious to improve air flue contraction in terms of air flue, to airway hyper-reaction with the effect of releiving；Secondly it is sensible depressing Qi and relieving asthma, for nasal obstruction, gas Anxious, syndrome characterized by dyspnea, improve the respectful drop function of lung.
Inventor clinically forms the aggregate analysis to asthma, and is analyzed according to disease diagnosis and treatment aspect of currently roaring, Think the understanding of " heat is roared, cold heavy breathing, and centered on phlegm, volt phlegm is long-standing phlegm ", be constantly subjected to pay close attention to, and textbook, many treatises are Prove repeatedly.And another group has intolerance factors basis, very cause that there is physiques and natural endowment, familial factor patient occupies larger proportion " wind heavy breathing " also sense demonstration is few, from wind, the opinion person of controlling is more inadequate, studies that to have carried out screening again according to clinical application true repeatedly This prescription is determined.
Using windproof, perilla leaf as monarch in the party, it is intended to dispelling wind, the meaning of antiallergic, and two medicines are also formed from wind opinion in clinic and controlled. Windproof, dispelling wind wind-dispelling is effective in cure to respiratory system anaphylactia.Perilla leaf, dispelling wind, to air flue illness class using more, the two There are dispelling wind facilitaing lung, the work(of antiallergic emergency；
Ephedra, aster, almond are ministerial drug in side, and Chinese ephedra is dispelling wind sending down abnormally ascending and big medicine of freeinging lung and relieving asthma, and treats asthma uncomfortable in chest The key medicine of heavy breathing, there is the experience that expert was also once apt to be treated asthma with Chinese ephedra；Aster, almond even more declare the gas of respectful lung, moistening lung to lower qi, pin Asthma of being felt suffocated to asthma is anxious and uses, and helps Chinese ephedra to tackle asthma attack altogether, or chronic sustained and control；
In side gingko, the fruit of Chinese magnoliavine, dogwood fruit receive gas astringe the lung, air flue of releiving, for clinical airway hyper-reaction Selected medicine with help monarch, ministerial drug in the hope of sending down abnormally ascending, receive gas, astringe the lung, Dingchuan, three medicines are adjutant；
The flower bud of lily magnolia, dispelling wind is sensible, also there is the curative effect of antiallergy, takes it to make medicine.
Full side did not belonged to cold, overheat side, and side is not cold not hot, i.e., " pungent put down based on " to control ailment said due to cold or exposure as trouble, to gas of releiving Road, dispersing and lowering lung-QI, it is not normal to nurse one's health respectful drop, relieving asthma and and it is sensible be method, see the total meaning of the treatment of wind card person to tackle asthma.
Embodiment
The beneficial effect of medicine of the present invention is expanded on further below by way of test example, these test examples include this The acute toxicity testing and pharmacodynamics test of invention medicine (hereinafter referred to as asthma side).
First, effect experiment：
1st, material
1.1 by reagent
Asthma side：It is prepared according to the method for embodiment 1.
1.2 comparison medicine
Dexamethasone acetate tablets：Specification 0.75mg/ pieces, lot number：130125201, Cisen Pharmaceutical Co., Ltd.
1.3 animal
SD rats 50, male, 180~200g of body weight, cleaning grade, Shanghai is western general and-Bi Kai experimental animals Co., Ltd, Quality certification number：(Shanghai) 2008-0016.
1.4 reagent
Ovalbumin OVA, article No.：A5503, (sigma)；Aluminium hydroxide Al (OH)3, article No. 239186, (sigma)；IL- 4th, IFN-γ and the kit of TGF-β 1, lot number 20141120, provided by Beijing China English biotechnology research institute.
2nd, experimental method
2.1 rat allergic asthma models are established
60 rats are divided into Normal group, asthmatic model group and Dexamethasone group 16.2mg/kg, asthma side at random High, medium and low dosage group, dosage are respectively 14g/kg, 7g/kg, 3.5g/kg.By the method for the reports such as Vanacker, asthma In the mixed liquid of every intraperitoneal injection antigen of d 0 and d 7, (OVA 1mg, the μ g of aluminium hydroxide 200, are dissolved in 1ml physiological saline to model mouse It is made into suspension) sensitization.D 14 starts to be excited, every two days 1 time, each 30min, totally 2 weeks with 1%OVA Ultrasonic atomising tarings. In d 0 and the 1ml physiological saline intraperitoneal injections of d 7, d14 starts to be inhaled with physiological saline ultrasonic atomizatio rats in normal control group Enter, every two days 1 time, each 30min, totally 2 weeks.Dexamethasone group and asthma side group rat its d 14 beginnings gavage give corresponding medicine Thing, 1ml/100g, totally 2 weeks.Normal group and asthmatic model group rat give equivalent CMC-Na solution in the gavages of d 14, and totally 2 Week.
2.2 Indexs measure
2.2.1 bronchoalveolar lavage (BALF) and collection of specimens
After each group rat last time excites 1h, after every rat is with 10% chloraldurate 35mg/kg intraperitoneal injection of anesthesia, Abdominal aortic blood is lethal.Sterilize and open thoracic cavity, ligature right main bronchus, tracheae is inserted with trachea cannula pin, after fixed, Row left pulmonary alveolar wass art.It is slowly injected into D-hanks liquid 5ml and stops 10s, slow pumpback, is repeated 3 times；Recovered liquid about 4ml. Recovered liquid injects EP pipes immediately, and 4 DEG C of 1500r/min centrifuge 15min.Acclimatization is taken to make cell smear, Rui Shi-Ji's nurse Safa dye Color, cell classification is carried out by morphological criteria.After remainder precipitation is diluted again with 4ml physiological saline, blood cell counting plate is added, Make cell count under the microscope.
2.2.2 IL-4, IFN-γ and TGF-β 1 are horizontal in serum
After each group rat last time excites 24h, every rat is with 10% chloraldurate 35mg/kg intraperitoneal injection of anesthesia Afterwards, abdominal aortic blood, 4 DEG C of 3000r/min centrifuge 10min, separate serum.
2.3 statistical procedures side operators according to this,Represent, with SPSS17.0 statistical softwares using single factor test variance point Analysis carries out statistical procedures.
3rd, experimental result
Total white blood cells, neutrophil leucocyte percentage measure in 3.1BALF
The asthma side of table 1 to total white blood cells in BALF, neutrophil leucocyte percentage influence (N=10)
Note：Compared with Normal group,△P ＜ 0.05,△△P ＜ 0.01；Compared with model group,#P ＜ 0.05,##P ＜ 0.01。
Compared with normal group, total white blood cells and the significantly raised (P of neutrophil leucocyte percentage in model group rats BALF< 0.01), compared with model group, the high, medium and low dosage group in asthma side can reduce total white blood cells and neutrophil leucocyte percentage, poor Different significantly (P<0.05).
IL-4, IFN-γ and TGF-β 1 are horizontal in 3.2 serum
The asthma side of table 2 to IL-4 in serum, IFN-γ and the horizontal influence of TGF-β 1 (N=10)
Note：Compared with Normal group,△P ＜ 0.05,△△P ＜ 0.01；Compared with model group,#P ＜ 0.05,##P ＜ 0.01。
Compared with normal group, IL-4, IFN-γ and the horizontal significantly rise (P of TGF-β 1 in model group rats serum<0.01), Compared with model group, the high, medium and low dosage group in asthma side can reduce IL-4, IFN-γ and the level of TGF-β 1 (P<0.01, P< 0.05)。
This result of the test shows that asthma side has obvious suppression to make to the Airway inflammatory response of rat asthma animal model With can reduce total white blood cells and neutrophil leucocyte percentage in BALF, it is horizontal to reduce serum IL -4, IFN-γ and TGF-β 1.
2nd, acute toxicity testing：
ICR mouse 40, female, tom are divided into 2 groups by body weight equilibrium respectively, each 10 of every group of male and female, respectively compareed Group and administration group；Administration group Mouse oral asthma side 400g crude drugs/kg, the oral constant volume test water of control group, volume is administered 40mL/kg, divide morning and afternoon 2 administrations, dosing interval is in 4~5h twice.Administration group and control group are dying or dead without animal Die, mouse single oral asthma particle maximal tolerance dose (MTD) is 400g crude drugs/kg, 325 times of about clinical plan dosage.
The preparation of 1 medicinal granule of the present invention of embodiment
The taste of the above nine, perilla leaf, flower bud of lily magnolia extraction by steam distillation volatile ingredient, using beta-cyclodextrin inclusion compound standby With the dregs of a decoction merge with windproof, ephedra, semen armeniacae amarae, and respectively plus 10 times of amount decoctings are boiled three times, 1.5 hours every time, merge extraction Liquid, clear cream (d=1.10~1.15,50 DEG C) is condensed into, alcohol is sink to alcohol content 70%, takes supernatant concentration that relative density is made and is The clear cream of 1.25~1.30 (50 DEG C) is standby；The fruit of Chinese magnoliavine, gingko, aster, dogwood fruit are extracted three times with 60% ethanol, and every time 2.5 Hour, merge alcohol extract, the clear cream that relative density is 1.25~1.30 (50 DEG C) is made in concentration；Above-mentioned each clear cream is merged, done It is dry, crush, add volatile oil clathrate compound mixing, then with appropriate customary adjuvant, mix, granulation, 1000g is made, produces.The day for human beings takes Dosage：15g-30g.
The preparation of the medicine decoction of the present invention of embodiment 2
Windproof 10g, perilla leaf 10g, ephedra 6g, fruit of Chinese magnoliavine 8g, gingko 8g, semen armeniacae amarae 8g, aster 8g, dogwood fruit 8g, Flower bud of lily magnolia 8g, add 10 times amount decoctings boil three times, 2.0 hours every time, merge decocting liquid, be condensed into clear cream (d=1.10~1.15,50 DEG C) decoction is made, day take one.
The preparation of 3 medicinal tablet of the present invention of embodiment
Windproof 150g perilla leafs 150g ephedras 60g fruit ofs Chinese magnoliavine 70g gingko 70g semen armeniacae amarae 70g aster 70g dogwood fruits 70g Flower bud of lily magnolia 70g.
The taste of the above nine, perilla leaf, flower bud of lily magnolia extraction by steam distillation volatile ingredient, using beta-cyclodextrin inclusion compound standby With the dregs of a decoction merge with windproof, ephedra, semen armeniacae amarae, and respectively plus 10 times of amount decoctings are boiled three times, 1.5 hours every time, merge extraction Liquid, clear cream (d=1.10~1.15,50 DEG C) is condensed into, alcohol is sink to alcohol content 70%, takes supernatant concentration that relative density is made and is The clear cream of 1.25~1.30 (50 DEG C) is standby；The fruit of Chinese magnoliavine, gingko, aster, dogwood fruit are extracted three times with 60% ethanol, and every time 2.5 Hour, merge alcohol extract, the clear cream that relative density is 1.25~1.30 (50 DEG C) is made in concentration；Above-mentioned each clear cream is merged, done It is dry, crush, add volatile oil clathrate compound mixing, then with appropriate customary adjuvant, mix, granulation, tabletting, be made 1000.
The preparation of 4 medicine capsule of the present invention of embodiment
Windproof 120g perilla leafs 120g ephedras 60g fruit ofs Chinese magnoliavine 80g gingko 80g semen armeniacae amarae 80g aster 80g dogwood fruits 80g Flower bud of lily magnolia 80g.
The taste of the above nine, perilla leaf, flower bud of lily magnolia extraction by steam distillation volatile ingredient, using beta-cyclodextrin inclusion compound standby With the dregs of a decoction merge with windproof, ephedra, semen armeniacae amarae, and respectively plus 10 times of amount decoctings are boiled three times, 1.5 hours every time, merge extraction Liquid, clear cream (d=1.10~1.15,50 DEG C) is condensed into, alcohol is sink to alcohol content 70%, takes supernatant concentration that relative density is made and is 1.25 the clear cream of~1.30 (50 DEG C) is standby；The fruit of Chinese magnoliavine, gingko, aster, dogwood fruit are extracted three times with 60% ethanol, and every time 2.5 Hour, merge alcohol extract, the clear cream that relative density is 1.25~1.30 (50 DEG C) is made in concentration；Above-mentioned each clear cream is merged, done It is dry, crush, add volatile oil clathrate compound mixing, then with appropriate customary adjuvant, mix, granulation, encapsulating capsule, be made 1000.

Claims (7)

  1. A kind of 1. Chinese medicine composition for treating allergic asthma, it is characterised in that said composition by following parts by weight component system Into：
    Windproof 10-15 parts by weight, perilla leaf 10-15 parts by weight, ephedra 2-6 parts by weight, fruit of Chinese magnoliavine 7-9 parts by weight, gingko 7-9 Parts by weight, semen armeniacae amarae 7-9 parts by weight, aster 7-9 parts by weight, dogwood fruit 7-9 parts by weight, flower bud of lily magnolia 7-9 parts by weight.
  2. 2. the Chinese medicine composition for the treatment of allergic asthma according to claim 1, it is characterised in that said composition is by as follows The component of parts by weight is made：
    Windproof 10-12 parts by weight, perilla leaf 10-12 parts by weight, ephedra 4-6 parts by weight, fruit of Chinese magnoliavine 7-8 parts by weight, gingko 7-8 Parts by weight, semen armeniacae amarae 7-8 parts by weight, aster 7-8 parts by weight, dogwood fruit 7-8 parts by weight, flower bud of lily magnolia 7-8 parts by weight.
  3. 3. the Chinese medicine composition for the treatment of allergic asthma according to claim 1, it is characterised in that said composition is by as follows The component of parts by weight is made：
    Windproof 10 parts by weight, the parts by weight of perilla leaf 10, the parts by weight of ephedra 6, the parts by weight of the fruit of Chinese magnoliavine 8, the parts by weight of gingko 8, bitter apricot The parts by weight of benevolence 8, the parts by weight of aster 8, the parts by weight of dogwood fruit 8, the parts by weight of the flower bud of lily magnolia 8.
  4. 4. the Chinese medicine composition of the treatment allergic asthma according to claim 1,2 or 3, it is characterised in that said composition adds The auxiliary material for entering pharmacy permission prepares decoction, granule, capsule, tablet or pill.
  5. 5. the preparation method of the Chinese medicine composition described in a kind of claim 1,2 or 3, it is characterised in that it comprises the following steps：
    By perilla leaf, flower bud of lily magnolia extraction by steam distillation volatile ingredient, using standby after beta-cyclodextrin inclusion compound, the dregs of a decoction with it is anti- Wind, ephedra, semen armeniacae amarae merge, and add water to cook 2-3 times respectively, each 1-3 hours, merge extract solution, are condensed into 50 DEG C of conditions Lower relative density is 1.10~1.15 clear cream, and alcohol is sink to alcohol content 60%-70%, takes supernatant concentration to be made under the conditions of 50 DEG C The clear cream that relative density is 1.25~1.30 is standby；The fruit of Chinese magnoliavine, gingko, aster, dogwood fruit extract 2-3 with 60%-70% ethanol It is secondary, each 1-3 hours, merge alcohol extract, the clear cream that relative density under the conditions of 50 DEG C is 1.25~1.30 is made in concentration；Will be above-mentioned Each clear cream merges, and dry, pulverize, and adds volatile oil clathrate compound, mixes, produces.
  6. 6. the preparation method of the Chinese medicine composition described in a kind of claim 5, it is characterised in that it comprises the following steps：
    By perilla leaf, flower bud of lily magnolia extraction by steam distillation volatile ingredient, using standby after beta-cyclodextrin inclusion compound, the dregs of a decoction with it is anti- Wind, ephedra, semen armeniacae amarae merge, and respectively plus 10 times of amount decoctings are boiled 3 times, 1.5 hours every time, are merged extract solution, are condensed into 50 DEG C Under the conditions of relative density be 1.10~1.15 clear cream, alcohol is sink to alcohol content 70%, takes supernatant concentration to be made under the conditions of 50 DEG C The clear cream that relative density is 1.25~1.30 is standby；The fruit of Chinese magnoliavine, gingko, aster, dogwood fruit 60% ethanol extraction 3 times, every time 2.5 hours, merge alcohol extract, the clear cream that relative density under the conditions of 50 DEG C is 1.25~1.30 is made in concentration；By above-mentioned each clear cream Merge, dry, pulverize, add volatile oil clathrate compound, mix, produce.
  7. 7. application of the Chinese medicine composition in the medicine for preparing treatment allergic asthma described in claim 1,2 or 3.
CN201510885057.9A 2015-12-06 2015-12-06 A kind of Chinese medicine composition for treating allergic asthma and preparation method thereof Active CN105412281B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510885057.9A CN105412281B (en) 2015-12-06 2015-12-06 A kind of Chinese medicine composition for treating allergic asthma and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510885057.9A CN105412281B (en) 2015-12-06 2015-12-06 A kind of Chinese medicine composition for treating allergic asthma and preparation method thereof

Publications (2)

Publication Number Publication Date
CN105412281A CN105412281A (en) 2016-03-23
CN105412281B true CN105412281B (en) 2018-02-13

Family

ID=55491130

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510885057.9A Active CN105412281B (en) 2015-12-06 2015-12-06 A kind of Chinese medicine composition for treating allergic asthma and preparation method thereof

Country Status (1)

Country Link
CN (1) CN105412281B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107764924B (en) * 2016-08-19 2020-01-31 江苏康缘药业股份有限公司 Detection method of effective components in asthma granules
CN107648285A (en) * 2017-10-26 2018-02-02 大连大学 Chinese ephedra non-alkaloids component is preparing the application in treating allergic asthma medicine
CN111317787A (en) * 2020-03-25 2020-06-23 漳州片仔癀药业股份有限公司 Application of traditional Chinese medicine composition and preparation thereof in preparation of medicine for treating bronchial asthma

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1266693A (en) * 2000-03-03 2000-09-20 马桂玲 Chinese medicinal composition for treating asthma and preparing process thereof
CN104983881A (en) * 2015-07-01 2015-10-21 北京东方运嘉科技发展有限公司 Traditional Chinese medicine composition for relieving cough and asthma as well as preparation method and application of traditional Chinese medicine composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1266693A (en) * 2000-03-03 2000-09-20 马桂玲 Chinese medicinal composition for treating asthma and preparing process thereof
CN104983881A (en) * 2015-07-01 2015-10-21 北京东方运嘉科技发展有限公司 Traditional Chinese medicine composition for relieving cough and asthma as well as preparation method and application of traditional Chinese medicine composition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
从风论治过敏性哮喘的文献整理和实验研究;李彦军;《中国优秀硕士学位论文全文数据库医药卫生科技辑2010年第11期》;20101115;全文 *
论过敏性疾病的中医药治疗;仝小林，等;《上海中医药大学学报》;20110930;第25卷(第5期);8-10 *

Also Published As

Publication number Publication date
CN105412281A (en) 2016-03-23

Similar Documents

Publication Publication Date Title
CN105412281B (en) A kind of Chinese medicine composition for treating allergic asthma and preparation method thereof
CN104784505A (en) Dendrobium officinale healthcare product with auxiliary blood glucose reducing function and preparation method thereof
CN103977315B (en) Medicinal composition for treating cough with wind-heat affecting lung and preparation method thereof
CN101549059B (en) Medicament for treating bronchial asthma and preparation method thereof
CN103446414B (en) Xiangmahanchuantie (XMHCT) and preparation technology
CN105169001B (en) A kind of Chinese medicine composition for treating cough variant asthma in childhood: prednison comparing
CN104740581B (en) A kind of application of cold asthma patch of fragrant fiber crops and its detection method
CN103566227B (en) A kind of Chinese medicine composition preventing and treating type 2 diabetes mellitus and preparation method thereof
CN102836203B (en) Traditional Chinese medicine composition for treating wind-heat type common cold as well as preparation method and application thereof
CN104524291A (en) Method for preparing medicine preparation for treating swine fever
CN104225201A (en) Medicinal composition for treating cough
CN104127544B (en) The application in preparing medicine of Murraya tetramera Huang and extract thereof
CN102579785B (en) Lung caring pill
CN102648956A (en) Traditional Chinese herbal medicament for treating breast cancer and preparation method thereof
CN112386671B (en) Traditional Chinese medicine composition for treating interstitial lung disease and application thereof
CN102240328A (en) Traditional Chinese medicine for treating cold and preparation method thereof
CN101940704A (en) Compound combination medicament for treating asthma and preparation method thereof
CN104491378A (en) Method for preparing medicine for treating bronchial asthma
CN104383238A (en) Medicine for treating bronchial asthma
CN105327198A (en) Heat-clearing and cough-relieving health care tea and preparation method and application thereof
CN104971298A (en) Pyrrosia leaf traditional Chinese medicine composition for treating phlegm-heat lung obstructing type asthma
CN104491637A (en) Compound combination medicine for treating postinfectious cough as well as preparation method and application of compound combination medicine
CN100350953C (en) Medicinal composition for treating high fever due to virus infection and its preparation method
CN106138687A (en) A kind of Chinese medicine composition preventing and treating the kidney deficiency type asthma
CN104524266A (en) Preparation method of ion introduction agent for treating children hyperthyroidism

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant